December 11, 2001

Immunomedics cancer imaging prodcut reported to improve detection of breast cancer metatastases

December 10, 2001

Immunomedics reports results with radiolabeled Epratuzumab

December 5, 2001

Immunomedics reviews progress at annual meeting of shareholders

November 20, 2001

Immunomedics awarded U.S. patent for infections disease therapy

November 9, 2001

Immunomedics reports fiscal first quarter 2002 results

November 2, 2001

Immunomedics to present at the CIBC World Markets 12th annual health care conference

October 25, 2001

Immunomedics licenses labeling technology for CLOT imaging agent to Agen Biomedical

October 25, 2001

Immunomedics to present at the Salomon Smith Barney Health Care Conference

October 1, 2001

Immunomedics to present at Raymond James Healthcare Conference in Nashville

September 11, 2001

Immunomedics appoints chief financial officer

August 8, 2001

Immunomedics reports fiscal 2001 results

July 26, 2001

Immunomedics patents new method of site-specific conjugation of drugs and isotopes to antibodies

June 27, 2001

Immunomedics and IBC Pharmaceuticals report preclinical and clinical studies with bispecific antibody cancer therapeutics

June 26, 2001

Clinical results with Immunomedics’ infectious disease imaging product reported at major medical conference

June 25, 2001

Immunomedics presents interim results on its radiolabeled CD22 antibody for the treatment of non-Hodgkin’s lymphoma

June 11, 2001

Australian patent awarded to Immunomedics for therapy of B-cell malignancies using anti-CD22 antibodies

May 30, 2001

Immunomedics awarded U.S. patent for boron neutron capture therapy using pre-targeting methods and bispecific antibodies

May 8, 2001

Immunomedics reports third quarter 2001 results

May 2, 2001

Immunomedics advances bispecific antibody technology for isotope or drug therapies of cancer

March 26, 2001

Immunomedics scientists invent improved method of labeling antibodies with radioiodine for cancer therapy

March 21, 2001

Immunomedics announces management changes

February 14, 2001

U.S. patent on positron emission tomography agents awarded to Immunomedics

February 13, 2001

Third U.S. patent awarded to Immunomedics for lymphoma treatment licensed to Amgen

February 8, 2001

Immunomedics reports second quarter 2001 results

February 6, 2001

Immunomedics granted U.S. patent for CD22 antibodies in lymphoma therapies

February 1, 2001

Immunomedics recieves up-front payment of $18mm from Amgen

January 8, 2001

Immunomedics to present at chase H&Q conference